TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of “Hold” from Analysts

TScan Therapeutics, Inc. (NASDAQ:TCRX) has been given an average rating of “Hold” by the seven analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $6.60.

A number of research analysts have commented on the stock. Morgan Stanley cut shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research report on Friday, November 14th. BTIG Research cut shares of TScan Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Wednesday, October 8th. Needham & Company LLC cut their price target on shares of TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, November 4th. Finally, HC Wainwright reduced their price objective on TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th.

Insider Transactions at TScan Therapeutics

In related news, major shareholder Lynx1 Capital Management Lp purchased 80,069 shares of TScan Therapeutics stock in a transaction that occurred on Friday, December 19th. The shares were acquired at an average cost of $0.90 per share, for a total transaction of $72,062.10. Following the transaction, the insider directly owned 7,937,416 shares in the company, valued at $7,143,674.40. The trade was a 1.02% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders purchased 161,801 shares of company stock worth $145,621. 4.35% of the stock is owned by company insiders.

Institutional Trading of TScan Therapeutics

A number of institutional investors have recently made changes to their positions in TCRX. Hsbc Holdings PLC bought a new stake in TScan Therapeutics in the 1st quarter worth $49,000. Checkpoint Capital L.P. raised its stake in shares of TScan Therapeutics by 14.9% during the first quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company’s stock valued at $2,784,000 after acquiring an additional 261,663 shares during the last quarter. BVF Inc. IL boosted its holdings in shares of TScan Therapeutics by 63.6% during the first quarter. BVF Inc. IL now owns 4,889,474 shares of the company’s stock worth $6,747,000 after purchasing an additional 1,900,000 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of TScan Therapeutics by 6.0% in the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock worth $235,000 after purchasing an additional 9,676 shares during the last quarter. Finally, Deutsche Bank AG increased its holdings in TScan Therapeutics by 149.4% during the 1st quarter. Deutsche Bank AG now owns 52,559 shares of the company’s stock valued at $73,000 after purchasing an additional 31,481 shares during the period. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Trading Up 2.0%

NASDAQ TCRX opened at $1.02 on Wednesday. The company has a quick ratio of 6.44, a current ratio of 6.44 and a debt-to-equity ratio of 0.23. The stock’s 50-day simple moving average is $1.14 and its two-hundred day simple moving average is $1.59. TScan Therapeutics has a twelve month low of $0.88 and a twelve month high of $3.21. The company has a market capitalization of $57.89 million, a price-to-earnings ratio of -0.91 and a beta of 1.04.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.07. The firm had revenue of $2.51 million for the quarter, compared to analyst estimates of $1.98 million. TScan Therapeutics had a negative return on equity of 73.33% and a negative net margin of 1,692.96%. Research analysts forecast that TScan Therapeutics will post -1.12 EPS for the current fiscal year.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.